This quietly trading NASDAQ company priced around $1…. is targeting a multi-billion market opportunity….
Greetings Investors,
Surgery... it's often a procedure that scares people and makes them want to avoid it at all costs. In today's modern world, healthcare is approaching surgical operations in a different manner. One that is giving many patients peace of mind.
This is what makes one emerging company on the NASDAQ so exciting.
Hurry and add NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) to your radar!
NMTC is a medical tech company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.
The company is a developer of best-in-class electrodes designed to diagnose and treat debilitating neurological conditions with a multi-billion market opportunity for combination devices.
The stock currently has a high price target of $3.25, representing an upside of over 100% compared to current levels!
Minimally invasive surgery (otherwise known as MIS) has taken the forefront of the surgical industry and NMTC could come out as one of the key players in it.
MIS presents a lot of benefits to patients compared to an open technique. The advantages range from reduced healthcare costs to smaller incisions, less scarring, increased accuracy, decreased risk of complications, less pain, and shorter recovery.
The advent of laparoscopic surgery in the 1980s started a revolution in MIS, which is continuing to expand as more patients want to avoid having surgery.
Today, MIS technology - like that of NMTC - is used in a wide range of procedures. This includes neurosurgery, gynecological, urological, and cardiovascular surgeries.
NMTC has been committed to providing minimally invasive and hi-definition solutions that may improve patient outcomes and reduce procedural costs for electroencephalograms (EEG) and brain stimulation, and ablation solutions for patients who have: epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders.
In other words, the company is offering a revolutionary approach for people who suffer from countless neurological disorders.
NMTC says it addresses current treatment challenges where electrodes are used to detect, record and monitor neurological activity and stimulate or ablate tissue to regulate brain activity.
Contrary to the use of electrodes, the company believes its new radiofrequency (RF) ablation system (OneRF® Ablation system) may offer detection, recording, and treatment in a procedure leading to higher patient satisfaction, lower patient risk, lower cost and improved accuracy.
Considering that the ablation devices market size garnered over $8.6 billion in revenues in 2022 and is predicted to exhibit above 9% compound annual growth rate (CAGR) from 2023 to 2032, there is a massive market here!
The company's CEO Dave Rosa made an appearance on The Claman Countdown on Fox Business in February last year and highlighted the groundbreaking technology the company has been working on.
This technology already has FDA clearance!
Highlighting Elon Musk's Neuralink, which is building a brain chip interface that can be implanted within the skull, Rosa explained that NeuroOne's technology is less invasive, near term and less complicated compared to Neuralink, which is complex and several years away from going commercial.
Watch the video on Fox Business for more here.
Major players in the global minimally invasive surgery market include Medtronic PLC (NYSE: MDT), Intuitive Surgical Inc. (NASDAQ: ISRG), and Globus Medical Inc. (NYSE: GMED).
Trading at under $2.00 and a market cap of just around $25M, NMTC could be strategically placed for growth and is a story to keep your eyes on!
https://n1mtc.com/
NeuroOne Medical Technologies Corp.
NASDAQ: NMTC
Company Overview:
NMTC is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.
Company Highlights:
- The company has a marketing and distribution partnership with Zimmer Biomet Holdings Inc. (NYSE: ZBH) for diagnostic applications; Anticipated launch of EVO® Cortical/EVO® sEEG electrodes in late Q1 2023 (more than $100 million market)
- An anticipated U.S. regulatory submission (510k) of OneRF® Ablation system in Q2 2023; for use with EVO sEEG® electrodes to treat neurologic conditions.
- Strategy to access the ablation market through additional partnerships leveraging the resources of commercial med tech companies; Zimmer has rights of first negotiation.
- The company's next-generation electrodes are in development for spinal cord and deep brain stimulation to treat chronic conditions such as Parkinson's disease, epilepsy, tremors, and chronic pain.
- There is a significant cash runway to achieve meaningful inflection points.
Dave Rosa, CEO of NeuroOne: "We believe our technology can fill a market need for improved patient outcomes due in part to its potential ability to place a paddle device through a needle, provide a larger stimulation surface area of the spinal cord, better conformability with the tissue and improve battery life of devices, reducing the frequency of patient's need to recharge or replace the battery."
Completion Of Initial Animal Implant of Novel Thin Film Paddle Lead For Spinal Cord Stimulation
NMTC recently completed the initial animal implant of its novel thin film paddle lead for spinal cord stimulation and is developing a percutaneous (through a needle) paddle lead placement system, which could eliminate the need for an incision in the patient's back.
The study evaluated the feasibility of implanting a variety of sizes and shapes of ultra-thin paddle leads in a sheep model. A mini laminectomy surgical approach was used to gain access to the epidural space for device placement. All devices were easily advanced to the target location in under one minute. A competitive silicone-based lead was also placed for comparison purposes. The NeuroOne lead fit comfortably in the epidural space and the veterinary surgeon reported no concerns regarding the placement of the lead.
These results demonstrated feasibility for placement of a thin film paddle lead intended to treat chronic back pain due to multiple failed back surgeries. More testing will be completed to optimize the design and placement. The Company is also developing a percutaneous (through a needle) paddle lead placement system which would eliminate the need for an incision in the patient's back. The preliminary bench top testing for this percutaneous approach has also been successfully completed.
This represents a major milestone for the company!
NMTC says it is also developing a percutaneous (through a needle) paddle lead placement system, which would eliminate the need for an incision in the patient's back. The preliminary benchtop testing for this percutaneous approach has also been completed.
Fiscal First Quarter 2023 and Recent Business Updates:
- Received FDA 510(k) clearance to market the Evo® sEEG Electrode technology for temporary (less than 30 day) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, enabling NeuroOne to fully address the $100M diagnostic electrode market.
- A feasibility animal study of the Company's OneRF® therapeutic radiofrequency ablation electrode system was completed under the guidance of Dr. Jamie Van Gompel at the Mayo Clinic in Rochester, MN. OneRF is an sEEG probe-guided RF based system to monitor and adjust settings based on temperature throughout an ablation, a feature designed to improve the safety of the procedure.
- The first commercial order of Evo® sEEG electrodes for temporary use (less than 30 days) was shipped to the Company's distribution and development partner Zimmer Biomet. NeuroOne continues to build up inventory to meet product forecasts and fulfill additional orders in-house.
- The Company developed and successfully bench tested an early prototype of a first-of-a-kind device that can deliver drugs (or other diagnostic or therapeutic agents) to the brain while also having the capability to stimulate and record before and after application.
- Held discussions with strategic organizations regarding the Company's technology in an effort to potentially expand the product footprint in neurology.
- Exhibited the Evo electrode product family with Zimmer Biomet at the Congress of Neurological Surgeons annual meeting and the American Epilepsy Society and Congress of Neurological Surgeons annual meetings.
- CEO Dave Rosa featured on Fox Business Network's 'Mornings with Maria.'
- Rang Nasdaq Stock Market closing bell to commemorate the FDA clearance milestone for Evo sEEG Electrode technology.
Upcoming Targeted Milestones:
- Commercial launch of Evo sEEG electrodes with Zimmer Biomet in the first quarter of calendar year 2023.
- Along with Zimmer Biomet, present the newly launched Evo sEEG system at the American Association of Neurological Surgeons (AANS) annual meeting at the end of April 2023.
- Submit a 510(k) application to the FDA for OneRF in the second quarter of calendar year 2023.
- Complete design verification testing for OneRF confirming that the full feature system meets its design specifications and is fully functional.
- Complete next in vivo animal testing of the OneRF system with multiple surgeons with the objective of gathering additional in vivo data on the system's performance.
- Pre-clinical implantation for spinal cord stimulation (SCS) electrodes intended for permanent implant to treat chronic pain.
The Bottom Line:
With the growing epidemic of neurological disorders from Epilepsy to Parkinson's Disease, and even chronic back pain and depression… it has become apparent to pay close attention to the companies tackling such disorders!
NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is an emerging and exciting player on the NASDAQ that is doing exactly just this!
How is this essentially undiscovered company potentially about to revolutionize healthcare? NMTC has developed a breakthrough thin-film electrode.
Thanks to strategic partnerships with Zimmer Biomet, the company anticipates that their technologies will be widely adopted in the near future.
Why should this breakthrough company be on your watchlist?
First, there is substantial market opportunity. Second, these are disruptive patented technologies. Third, the technology addresses a significant and unmet need and
there could be substantially improved outcomes.
AND… these are already FDA cleared electrodes!
All of this reads like a recipe for success and NMTC may be one of the most exciting narratives to emerge on the NASDAQ that has a price target over 100% higher than current levels!
Start your research right away!
没有评论:
发表评论